1. Lazebnik L.B., Turkina S. V., Myazin R. G. et al. Results of a multicenter prospective observational study “Clinical significance of hyperammonemia in patients with post-Covid syndrome (LIRA - COVID)”: efficacy of L-ornithine L-aspartate. Experimental and Clinical Gastroenterology. 2022;(11):5-16. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-207-11-5-16.@@ Lazebnik L. B., Turkina S. V., Myazin R. G. i soavt. Effektivnost' L-ornitin L-aspartata (LOLA) dlya korrektsii kognitivnykh i gepatotropnykh rasstroistv v postkovidnom periode: rezul'taty mnogotsentrovogo prospektivnogo nablyudatel'nogo issledovaniya «Klinicheskoe znachenie giperammoniemii u patsientov s postkovidnym sindromom (LIRA-COVID)». Eksperimental'naya i klinicheskaya gastroenterologiya. 2022;(11):5-16. https://doi.org/10.31146/1682-8658-ecg-207-11-5-16.
2. Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr. 2021;15(3):869-875. https://doi.org/10.1016/j.dsx.2021.04.007.
3. Maev I.V., Andreev D. N., Kucheryavyy Yu. A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313-319. (In Russ.) https://doi.org/10.26442/20751753.2023.5.202155.@@ Maev I. V., Andreev D. N., Kucheryavyi Yu. A. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni v Rossii: metaanaliz. Consilium Medicum. 2023;25(5):313-319. https://doi.org/10.26442/20751753.2023.5.202155.
4. Pan L., Mu M., Yang P., Et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross- Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-773. https://doi.org/10.14309/ajg.0000000000000620.
5. Sachdeva S, Khandait H, Kopel J. et al. NAFLD and COVID-19: a Pooled Analysis. SN Compr Clin Med. 2020;2(12):2726-2729. https://doi.org/10.1007/s42399-020-00631-3.
6. Alekseenko S.A., Ageeva E. A., Polkovnikova O. P. Modern approaches to diagnostics and treatment of hyperammonemia in patients with chronic liver disease at a precirrhotic stage. RMJ. Medical Review. 2018;7(1):19-23. (In Russ.)@@ Alekseenko S. A., Ageeva E. A., Polkovnikova O. P. Sovremennye podkhody k diagnostike i lecheniyu giperammoniemii u patsientov s khronicheskimi zabolevaniyami pecheni na dotsirroticheskoi stadii. RMZh. Meditsinskoe obozrenie. 2018;7(1):19-23.
7. Ermolova T.V., Ermolov S. Yu., Belova A. A. Ammonia - new therapeutic target for chronic liver diseases. Experimental and Clinical Gastroenterology. 2020; 4(176):5-16. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-24-30.@@ Ermolova T. V., Ermolov S. Yu., Belova A. A. Ammiak - novaya terapevticheskaya mishen' pri khronicheskikh zabolevaniyakh pecheni. Eksperimental'naya i klinicheskaya gastroenterologiya. 2020; 4(176):24-30. https://doi.org/10.31146/1682-8658-ecg-176-4-24-30.
8. Chen F., Chen W., Chen J. et al. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. Ann Hepatol. 2021;21:100267. https://doi.org/10.1016/j.aohep.2020.09.01126.
9. Ridruejo E., Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020 JulAug;19(4):353-358. https://doi.org/10.1016/j.aohep.2020.05.001.
10. Lazebnik L.B., Golovanova E. V., Alekseenko S. A. et al.Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English). Experimental and Clinical Gastroenterology. 2021;(12):154-172. https://doi.org/10.31146/1682-8658-ecg-196-12-154-172.
11. Riazi K., Azhari H., Charette J. H., Underwood F. E. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. https://doi.org/10.1016/S2468-1253(22)00165-0.
12. Portincasa P., Krawczyk M., Smyk W., Lammert F., Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50(10): e13338. https://doi.org/10.1111/eci.13338.
13. Thomsen K.L., Eriksen P. L., Kerbert A. J. et al. Role of ammonia in NAFLD: An unusual suspect. JHEP Rep. 2023;5(7):100780. https://doi.org/10.1016/j.jhepr.2023.100780.
14. Aldridge D.R., Tranah E. J., Shawcross D. L. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5(Suppl 1): S7-S20. https://doi.org/10.1016/j.jceh.2014.06.004.
15. Felipo V., Urios A., Montesinos E. et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012;27(1):51-8. https://doi.org/10.1007/s11011-011-9269-3.
16. Jalan R., De Chiara F., Balasubramaniyan V. et al. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol. 2016(4):823-33. https://doi.org/10.1016/j.jhep.2015.11.019.
17. Mukhametova D.D., Belousova E. N., Fashieva Z. I. et al. Evaluation of Hyperammonemia and Cognitive Impairment in post-COVID patients. Experimental and Clinical Gastroenterology. 2023;(8):66-72. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-216-8-66-72.@@ Mukhametova D. D., Belousova E. N., Faskhieva Z. I. i soavt. Otsenka giperammoniemii i kognitivnykh narushenii u patsientov v postkovidnom periode. Eksperimental'naya i klinicheskaya gastroenterologiya. 2023;(8):66-72. https://doi.org/10.31146/1682-8658-ecg-216-8-66-72.
18. Milic J., Barbieri S., Gozzi L. et al. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis. 2022 Jan 10;9(3): ofac003. https://doi.org/10.1093/ofid/ofac003.
19. Hadizadeh F., Faghihimani E., Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol. 2017 May 15;8(2):11-26. https://doi.org/10.4291/wjgp.v8.i2.11.
20. Plotnikova E.Y., Sinkova M. N., Isakov L. K. Asthenia and fatigue in hyperammonemia: etiopathogenesis and methods of correction. Medical Council. 2021;(21-1):95-104. (In Russ). https://doi.org/10.21518/2079-701X-2021-21-1-95-104.@@ Plotnikova E. Yu., Sin'kova M. N., Isakov L. K. Asteniya i utomlenie pri giperammoniemii: etiopatogenez i metody korrektsii. Meditsinskii sovet. 2021;(21-1):95-104. https://doi.org/10.21518/2079-701X-2021-21-1-95-104.
21. Sas E. I. Use of L-ornithine-L-aspartate in patients with non-alcoholic fatty liver disease. Medical alphabet. 2018;1(7):17-21. (In Russ.)@@ Sas E. I. Primenenie L-ornitina-L-aspartata u patsientov s nealkogol'noi zhirovoi bolezn'yu pecheni. Meditsinskii alfavit. 2018;1(7):17-21.
22. Butterworth R.F., Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2019;37(1):63-68. https://doi.org/10.1159/000491429.
23. Canbay A., Sowa J. P. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs. 2019;79(Suppl 1):39-44. https://doi.org/10.1007/s40265-018-1020-5.
24. Butterworth R.F., Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):24-30. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-1-24-30.@@ Battervort R. F., Kanbei A. Gepatoprotektsiya s ispol'zovaniem L-ornitina-L-aspartata pri nealkogol'noi zhirovoi bolezni pecheni. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2019;29(1):24-30. https://doi.org/10.22416/1382-4376-2019-29-1-24-30.
25. Najmi A.K., Pillai K. K., Pal S. N., Akhtar M., Aqil M., Sharma M. Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats. Indian J Pharmacol. 2010;42(6):384-7. https://doi.org/10.4103/0253-7613.71926.
26. Kizova E. A., Potekhina Yu. P. Effect of l-ornithine-l-aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;169(9): 80-84. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-169-9-80-84.@@ Kizova E. A., Potekhina Yu. P. Vliyanie terapii preparatom l-ornitin-l-aspartat na uroven' giperammoniemii i rezul'taty testa svyazyvaniya chisel u patsientov s nealkogol'noi zhirovoi bolezn'yu pecheni. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019;169(9): 80-84. https://doi.org/10.31146/1682-8658-ecg-169-9-80-84.
27. Garanina E. V. Effect of L-Ornithine-L-Aspartate on Liver Fibrosis and Steatosis in Patients with Metabolic-Associated Fatty Liver Disease (Non-alcoholic Fatty Liver Disease) and Hyperammonaemia.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):31-36. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-4-31-36.@@ Garanina E. V. Vliyanie kursovogo priema L-ornitin-L-aspartata na fibroz i steatoz pecheni u bol'nykh assotsiirovannoi s narusheniyami metabolizma zhirovoi bolezn'yu pecheni (nealkogol'noi zhirovoi bolezn'yu pecheni), imeyushchikh giperammoniemiyu. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2021;31(4):31-36. https://doi.org/10.22416/1382-4376-2021-31-4-31-36.